Antibody Response After Single H1N1 Influenza Vaccine in Chronic Dialysis Patients

Department of Nephrology, Ankara Education and Research Hospital Department of Virology, Refik Saydam National Public Health Agency, Ankara, Turkey.
Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Impact Factor: 1.71). 02/2013; 17(1):55-9. DOI: 10.1111/j.1744-9987.2012.01133.x
Source: PubMed


The first influenza pandemic of this century happened through a rapid spread of a novel swine-derived H1N1 influenza virus. Vaccines are produced in order to avoid the infection. Children and other high risk groups are highly recommended for vaccination due to the high probability of contracting the virus. Chronic kidney disease patients were also accepted as a risk group and vaccination of all patients undergoing hemodialysis or peritoneal dialysis was recommended. The results of H1N1 influenza virus vaccine on patients receiving hemodialysis and peritoneal dialysis are analyzed. Antibody titers of both hemodialysis and peritoneal dialysis patients were elevated after vaccination. Peritoneal dialysis patients responded better.

Download full-text


Available from: Alper Azak,
32 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Infections are an important cause of morbidity and mortality among patients at all stages of chronic kidney disease. Prevention through vaccination remains the best strategy to minimize the adverse consequences associated with these infectious diseases in this, and all, populations. Unfortunately, patients with chronic kidney disease demonstrate inadequacies of specific immune-cell function that are required for generating a protective vaccine response. Nevertheless, early vaccination of this high-risk population has demonstrated good clinical outcomes during progression to late-stage disease. We review the available evidence linking immune impairment in adult patients with late-stage chronic kidney disease to diminished vaccine responses. We highlight the importance of early vaccination in disease with high risk for development of CKD and novel vaccine approaches in development that may help to address improvement in protective boosting of immunity during late-stage disease.
    Expert Review of Vaccines 01/2014; 13(2). DOI:10.1586/14760584.2014.874950 · 4.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Patients with end-stage renal disease (ESRD) are considered at higher risk of influenza-related complications and are listed worldwide among the subjects for whom yearly influenza vaccination is strongly recommended. However, influenza vaccination coverage of patients with ESRD is significantly lower than desired. Areas covered: This paper explores why compliance with official recommendations for influenza vaccination is poor in patients with ESRD and analyzes the true risk of infection as well as the immunogenicity, the effectiveness and the safety of influenza vaccination in these patients. Expert opinion: Epidemiological and clinical data support the importance of influenza in conditioning clinical deterioration of patients with ESRD, particularly in relation to their level of immunosuppression. However, the variable levels of immunodeficiency detected in patients with ESRD may reduce the immune response to influenza vaccination, which appears to be lower than that usually found in healthy subjects. However, few studies are available, and they are difficult to compare for several reasons. Additionally, limited data have been collected on influenza vaccine effectiveness, although the available studies support positive results of vaccination on outcomes of severe disease. Despite such limitations, it is important to highlight that all the available studies have confirmed the good safety and tolerability of inactivated influenza vaccines. These findings, together with the risks associated with influenza in these patients, support annual influenza vaccination in patients with ESRD as well as vaccination of their close contacts and should be presented in educational programs organized for nephrologists and patient associations.
    Expert Opinion on Drug Safety 06/2015; 14(8):1-10. DOI:10.1517/14740338.2015.1053459 · 2.91 Impact Factor